Results 101 to 110 of about 6,666,035 (292)

Essential oncology nursing care along the cancer continuum

, 2020
Oncology nurses are at the heart of tackling the increasing global burden of cancer. Their contribution is unique because of the scale and the diversity of care roles and responsibilities in cancer care.
Owen, RI, Njodzeka, B, Alqudimat, Mohammad R., Young, Annie M., Alqudimat, MR, Charalambous, Andreas, Oldenmenger, Wendy, So, WKW, Njodzeka, Bernard, So, Winnie K W, Owen, Ray I., Oldenmenger, Wendy; id_orcid, Young, AMH, Oldenmenger, Wendy H., Charalambous, A   +14 more
core   +1 more source

Pathological Complete Response and Safety of Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy in Triple-Negative and Hormone Receptor-Low Breast Cancer: A Real-World Cohort Study

Breast Cancer: Targets and Therapy
Baha Sharaf,1 Tamer Albatsh,1 Suhaib Khater,1 Rawaa Alrabie,2 Abdallah Obidat,2 Tala Al-Bdour,2 Mohammad Alzoubi,3 Mohammad Sami Al-Qannas,4 Ahmed Alriqib Snr,1 Bashar Darawsheh,1 Tala Mzahreh,1 Ahmad Alazaideh,1 Huthaifa Albursan,1 Fahmi AL Nemrawi,1 ...
Sharaf B, Albatsh T, Khater S, Alrabie R, Obidat A, Al-Bdour T, Alzoubi M, Al-Qannas MS, Alriqib Snr A, Darawsheh B, Mzahreh T, Alazaideh A, Albursan H, Nemrawi FAL, Jehad S   +14 more
doaj  

Supplementum 265: Abstracts of the Swiss Oncology & Hematology Congress (SOHC), November 16-18, 2022

Swiss Medical Weekly, 2022
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China

Breast Cancer: Targets and Therapy
Yuxin Yan,1,2 Yizi Jin,1,2 Mingxi Lin,1,2 Ceng Zeng,1,2 Qing Guo,1,2 Teng Zhou,1,2 Dou Dou Li,3 Jian Zhang1,4 1Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 2Department of Breast and Urinary ...
Yan Y, Jin Y, Lin M, Zeng C, Guo Q, Zhou T, Li DD, Zhang J   +7 more
doaj  

Multidisciplinary Oncology Education Among Postgraduate Trainees: Systematic Review

JMIR Medical Education
BackgroundUnderstanding the roles and patient management approaches of the entire oncology team is imperative for effective communication and optimal cancer treatment.
Houman Tahmasebi, Gary Ko, Christine M Lam, Idil Bilgen, Zachary Freeman, Rhea Varghese, Emma Reel, Marina Englesakis, Tulin D Cil   +8 more
doaj   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Clinical implications of deregulated CDK4 and Cyclin D1 expression in patients with human hepatocellular carcinoma

, 2013
[[abstract]]Deregulated cell cycle can contribute to the unscheduled proliferation in cancer cells. Overexpression of cell cycle regulators CDK4 and Cyclin D1 has been reported in many cancers.

core  

A Retrospective Analysis of Testicular Cancer (2007–2025): A Single Institutional Experience

Research and Reports in Urology
Hamza Abedallaa,1 Zuheir Al-Shehabi,2,3 Nader Abedallaa41Faculty of Medicine, Latakia University, Latakia, Syria; 2Cancer Research Center (CRCTU), Latakia University Hospital, Latakia, Syria; 3Department of Pathology, Latakia University, Latakia, Syria ...
Abedallaa H, Al-Shehabi Z, Abedallaa N
doaj  

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source